siRNA therapeutic targeting PCSK9. Inclisiran is a GalNAc-conjugated small interfering RNA that reduces hepatic PCSK9 production to lower LDL cholesterol with twice-yearly maintenance dosing. Available for research, development and custom synthesis projects.